Premium
Suplatast Tosilate (IPD®), a New Immunoregulator, Is Effective in Vitiligo Treatment
Author(s) -
Nihei Yoshimichi,
Nishibu Akiko,
Kaneko Fumio
Publication year - 1998
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1998.tb02391.x
Subject(s) - vitiligo , medicine , dermatology , autoimmunity , autoantibody , immunology , antibody
The major type of vitiligo is considered to be an autoimmune disorder. Anti‐melanocyte antibodies are frequently detected in sera of patients with this disease. Interleukin (IL)‐4 released from Th2 cells is an important factor in stimulating autoantibody production by B‐cells. In this study, seven patients with vitiligo treated with suplatast tosilate (IPD), three showed repigmentation and improvement of their lesions after administration of the drug. IPD halted the continuous spread of the lesions in three of the other patients, and, in two of them, also reduced microsome test and thyroid test titers. The efficacy of IPD in treating vitiligo was thought to be due to the suppressive effect of this drug on IL‐4 production. No side effect was observed. Thus IPD may represent a new alternative in vitiligo treatment due to its inhibition of autoimmunity by the suppression of IL‐4.